Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers

Ioulia Chatzistamou, Andrew V Schally, Hippokratis Kiaris, Ekaterini Politi, Jozsef Varga, George Kanellis, Anastasios Kalofoutis, Agatha Pafiti, Helen Koutselini

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: CHRH is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates growth hormone (GH) production and release from the pituitary. In addition to this neuroendocrine action, accumulated evidence implies additional roles for GHRH in carcinogenesis in non-pituitary tissues. In vitro and in vivo studies have shown that splice variant 1 (SV1) of the GHRH receptor, which is widely expressed in non-pituitary tissues and cancers, can mediate the proliferative effects of GHRH. The aim of the present study was to investigate the operation of an autocrine stimulatory loop between GHRH and SV1 in primary breast tumors. Design: Fifty-three primary breast tumors were evaluated for GHRH and SV1 expression. Methods: Expression of GHRH and SV1 was assessed by immunohistochemistry using anti-GHRH SV95 and anti-SV1 2317/5 polyclonal antibodies. Results: About 40% of the specimens tested express GHRH and/or SV1 (approx. 25% each), while in 35% of these positive specimens co-expression of these antigens was detected (P < 0.01). Furthermore, a correlation of GHRH, but not SV1, expression was detected in lobular compared with ductal carcinomas. Conclusions: These results constitute the first demonstration for the expression of GHRH and SV1 in primary breast cancers, and provide evidence for the operation of an autocrine stimulatory loop between GHRH and SV1 in primary cancers. Our findings indicate that GHRH analogs could have diagnostic and therapeutic applications for the management of breast cancer.

Original languageEnglish
Pages (from-to)391-396
Number of pages6
JournalEuropean Journal of Endocrinology
Volume151
Issue number3
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Breast Neoplasms
Ductal Carcinoma
Growth Hormone
Hypothalamus
Neoplasms
Carcinogenesis
Immunohistochemistry
Antigens
somatotropin releasing hormone receptor
Antibodies
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Endocrinology

Cite this

Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. / Chatzistamou, Ioulia; Schally, Andrew V; Kiaris, Hippokratis; Politi, Ekaterini; Varga, Jozsef; Kanellis, George; Kalofoutis, Anastasios; Pafiti, Agatha; Koutselini, Helen.

In: European Journal of Endocrinology, Vol. 151, No. 3, 01.09.2004, p. 391-396.

Research output: Contribution to journalArticle

Chatzistamou, I, Schally, AV, Kiaris, H, Politi, E, Varga, J, Kanellis, G, Kalofoutis, A, Pafiti, A & Koutselini, H 2004, 'Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers', European Journal of Endocrinology, vol. 151, no. 3, pp. 391-396. https://doi.org/10.1530/eje.0.1510391
Chatzistamou, Ioulia ; Schally, Andrew V ; Kiaris, Hippokratis ; Politi, Ekaterini ; Varga, Jozsef ; Kanellis, George ; Kalofoutis, Anastasios ; Pafiti, Agatha ; Koutselini, Helen. / Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. In: European Journal of Endocrinology. 2004 ; Vol. 151, No. 3. pp. 391-396.
@article{2a769e7b17934ba8acd237c651281f70,
title = "Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers",
abstract = "Objective: CHRH is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates growth hormone (GH) production and release from the pituitary. In addition to this neuroendocrine action, accumulated evidence implies additional roles for GHRH in carcinogenesis in non-pituitary tissues. In vitro and in vivo studies have shown that splice variant 1 (SV1) of the GHRH receptor, which is widely expressed in non-pituitary tissues and cancers, can mediate the proliferative effects of GHRH. The aim of the present study was to investigate the operation of an autocrine stimulatory loop between GHRH and SV1 in primary breast tumors. Design: Fifty-three primary breast tumors were evaluated for GHRH and SV1 expression. Methods: Expression of GHRH and SV1 was assessed by immunohistochemistry using anti-GHRH SV95 and anti-SV1 2317/5 polyclonal antibodies. Results: About 40{\%} of the specimens tested express GHRH and/or SV1 (approx. 25{\%} each), while in 35{\%} of these positive specimens co-expression of these antigens was detected (P < 0.01). Furthermore, a correlation of GHRH, but not SV1, expression was detected in lobular compared with ductal carcinomas. Conclusions: These results constitute the first demonstration for the expression of GHRH and SV1 in primary breast cancers, and provide evidence for the operation of an autocrine stimulatory loop between GHRH and SV1 in primary cancers. Our findings indicate that GHRH analogs could have diagnostic and therapeutic applications for the management of breast cancer.",
author = "Ioulia Chatzistamou and Schally, {Andrew V} and Hippokratis Kiaris and Ekaterini Politi and Jozsef Varga and George Kanellis and Anastasios Kalofoutis and Agatha Pafiti and Helen Koutselini",
year = "2004",
month = "9",
day = "1",
doi = "10.1530/eje.0.1510391",
language = "English",
volume = "151",
pages = "391--396",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers

AU - Chatzistamou, Ioulia

AU - Schally, Andrew V

AU - Kiaris, Hippokratis

AU - Politi, Ekaterini

AU - Varga, Jozsef

AU - Kanellis, George

AU - Kalofoutis, Anastasios

AU - Pafiti, Agatha

AU - Koutselini, Helen

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Objective: CHRH is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates growth hormone (GH) production and release from the pituitary. In addition to this neuroendocrine action, accumulated evidence implies additional roles for GHRH in carcinogenesis in non-pituitary tissues. In vitro and in vivo studies have shown that splice variant 1 (SV1) of the GHRH receptor, which is widely expressed in non-pituitary tissues and cancers, can mediate the proliferative effects of GHRH. The aim of the present study was to investigate the operation of an autocrine stimulatory loop between GHRH and SV1 in primary breast tumors. Design: Fifty-three primary breast tumors were evaluated for GHRH and SV1 expression. Methods: Expression of GHRH and SV1 was assessed by immunohistochemistry using anti-GHRH SV95 and anti-SV1 2317/5 polyclonal antibodies. Results: About 40% of the specimens tested express GHRH and/or SV1 (approx. 25% each), while in 35% of these positive specimens co-expression of these antigens was detected (P < 0.01). Furthermore, a correlation of GHRH, but not SV1, expression was detected in lobular compared with ductal carcinomas. Conclusions: These results constitute the first demonstration for the expression of GHRH and SV1 in primary breast cancers, and provide evidence for the operation of an autocrine stimulatory loop between GHRH and SV1 in primary cancers. Our findings indicate that GHRH analogs could have diagnostic and therapeutic applications for the management of breast cancer.

AB - Objective: CHRH is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates growth hormone (GH) production and release from the pituitary. In addition to this neuroendocrine action, accumulated evidence implies additional roles for GHRH in carcinogenesis in non-pituitary tissues. In vitro and in vivo studies have shown that splice variant 1 (SV1) of the GHRH receptor, which is widely expressed in non-pituitary tissues and cancers, can mediate the proliferative effects of GHRH. The aim of the present study was to investigate the operation of an autocrine stimulatory loop between GHRH and SV1 in primary breast tumors. Design: Fifty-three primary breast tumors were evaluated for GHRH and SV1 expression. Methods: Expression of GHRH and SV1 was assessed by immunohistochemistry using anti-GHRH SV95 and anti-SV1 2317/5 polyclonal antibodies. Results: About 40% of the specimens tested express GHRH and/or SV1 (approx. 25% each), while in 35% of these positive specimens co-expression of these antigens was detected (P < 0.01). Furthermore, a correlation of GHRH, but not SV1, expression was detected in lobular compared with ductal carcinomas. Conclusions: These results constitute the first demonstration for the expression of GHRH and SV1 in primary breast cancers, and provide evidence for the operation of an autocrine stimulatory loop between GHRH and SV1 in primary cancers. Our findings indicate that GHRH analogs could have diagnostic and therapeutic applications for the management of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=4744362859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744362859&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1510391

DO - 10.1530/eje.0.1510391

M3 - Article

C2 - 15362970

AN - SCOPUS:4744362859

VL - 151

SP - 391

EP - 396

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -